THE WELLCOME TRUST/CANCER RESEARCH UK INSTITUTE

2002 PROSPECTUS/ANNUAL REPORT 2001
CONTENTS

THE INSTITUTE IN 2001

CHAIRMAN’S INTRODUCTION ................................................ 3
HISTORICAL BACKGROUND ..................................................... 4
PROFESSOR SIR JOHN GURDON ........................................... 5
CENTRAL SUPPORT SERVICES ............................................... 6
FUNDING .................................................................................. 6
INSTITUTE FACILITIES .......................................................... 7
NEW BUILDING .......................................................................... 7
INSTITUTE RETREAT .................................................................... 7

RESEARCH GROUPS .............................................................. 8

FOUR-YEAR RESEARCH GRANT HOLDERS ............................. 40

MEMBERS OF THE INSTITUTE

CATEGORIES OF APPOINTMENT .............................................. 42
POSTGRADUATE OPPORTUNITIES ........................................ 42
SENIOR GROUP LEADERS ...................................................... 42
GROUP LEADERS ....................................................................... 47
SUPPORT STAFF ........................................................................ 51

INSTITUTE PUBLICATIONS ................................................... 53

OTHER INFORMATION

STAFF AFFILIATIONS ............................................................ 59
HONOURS AND AWARDS ....................................................... 59
EDITORIAL BOARDS OF JOURNALS .................................... 59
INTERNATIONAL ADVISORY BOARD ................................... 59
LEAVERS DURING 2001 .......................................................... 60
ACKNOWLEDGEMENTS ......................................................... Inside back cover
CHAIRMAN’S INTRODUCTION

I write my first Introduction to this Prospectus two months after taking over the Chairmanship of the Institute from Professor Sir John Gurdon. We pay tribute to John’s magnificent work in chairing the Institute and bringing it to its present level of success below. All I should say here is how pleased we are that John will remain in the Institute as a Wellcome Trust-funded Group Leader, and how conscious I am of what a hard act he will be to follow!

This is an exciting time to work at the Wellcome Trust/Cancer Research UK Institute. As described below, we have a new building on the way, we have recently been awarded funds to establish a microarray facility, and we have been joined by two new Group Leaders. We are also enthusiastic participants in a new Wellcome Trust Four-Year PhD programme, of which Daniel St Johnston is a co-organiser.

We are delighted that several present and former members of the Institute have received national and international recognition of their work this year. Martin Evans, who left the Institute in 2000, was awarded the Lasker Prize for his pioneering work in developing embryonic stem cells; John Gurdon was awarded the Conklin Medal of the Society for Developmental Biology; Azim Surani was awarded the Royal Society’s Gabor Medal; Anne McLaren received the Unesco/L’Oreal Women in Science Award (Europe) as well as the US Society for Developmental Biology Award for Lifetime Scientific Achievement; Tony Kouzarides was made the Royal Society Napier Research Professor, awarded the Tenovus Medal, and received the Wellcome Trust Award for Research in Biochemistry related to medicine; Steve Jackson received the Anthony Dipple Carcinogenesis Young Investigator Award; Magda Zernicka-Goetz was made an EMBO Young Investigator, and Andrea Brand was awarded the Hooke Medal of the British Society for Cell Biology. Azim Surani, Steve Jackson and Tony Kouzarides were elected as Fellows of the Academy of Medical Sciences. Our congratulations to all.
As John Gurdon wrote last year, Ron Laskey has moved to become Director of the new MRC Cancer Cell Unit in the Cambridge Medical School. John had worked alongside Ron for one third of a century; I overlapped with Ron at the Wellcome/CRC Institute for only a year. Nevertheless, I quickly learned to value Ron’s sage advice on many matters as much as I admired his science. Like everyone I’ll miss him, and we wish him well.

New Group Leaders include Rick Livesey, who joins us from Harvard Medical School and brings expertise in microarray analysis to complement his work on the specification of neural cell types, and Magdalena Zernicka-Goetz who is studying early events in mouse development and was previously a Lister Fellow in the Institute. We are pleased that Jon Pines has been made a Senior Group Leader.

Readers of this prospectus will have noticed that the Institute has changed its name. This reflects the merger, on the 4th of February 2002, of the Cancer Research Campaign and the Imperial Cancer Research Fund. The fusion of the two charities makes Cancer Research UK the largest volunteer-supported cancer research organisation in the world and the largest funder of cancer research in the United Kingdom. We look forward to playing a full and active part in the success of this exciting new enterprise.

Finally, I should like to thank all the members of the Institute for making me so welcome; I look forward to working with everyone to ensure that the Institute’s second decade is as successful as its first.

Jim Smith, Chairman

HISTORICAL BACKGROUND

The Institute is situated in the middle of the area containing the science departments of the University of Cambridge and within a short distance from the centre of the historic city. It was founded in 1989 to promote research in the areas of developmental biology and cancer biology, and is an assemblage of independent research groups located in one building designed to promote as much interaction as possible.

Developmental and cancer biology are complementary since developmental biology is concerned with how cells acquire and maintain their normal function, whereas cancer is a result of a cell breaking loose from its correct controls and becoming abnormal. Both areas require a detailed knowledge
of intercellular processes, which need to be analysed at the cellular and molecular levels. These research areas are complementary at the scientific and technical levels. To understand what goes wrong when a cell becomes cancerous requires a knowledge of the processes that ensure correct function in normal development.

At the technical level, the analysis of cellular and molecular processes requires familiarity with techniques that no single person can master, such as gene cloning, antibody preparation, cell culture, and embryonic manipulation. There is, therefore, a major benefit in having scientists with different but complementary knowledge and technical skills working in close proximity to one another.

The major sponsors of our Institute are the Wellcome Trust and Cancer Research UK, and Group Leaders are normally funded in large part by one or the other organisation. The Institute is an integrated part of Cambridge University, and all Group Leaders are affiliated to a University Department and contribute to teaching and graduate student supervision.

**PROFESSOR SIR JOHN GURDON**

John Gurdon, who has now retired from his position as Chairman of the Wellcome/CRC Institute, has been and continues to be one of the most influential developmental biologists of our time. John has made seminal contributions to at least three areas of developmental biology, namely nuclear transplantation and cloning, the use of *Xenopus* eggs and oocytes for mRNA microinjection, and intercellular signalling during embryonic development. As a result of this work, John has received honorary degrees and awards too many to mention, but including, as we all know, a Knighthood for services to developmental biology.

As outlined in a recent interview in the International Journal of Developmental Biology, we are fortunate that John entered science at all, for at school he was regarded as being not only unsuited for science but also the worst pupil the Biology master had ever taught in his whole career! However, he received encouragement from other teachers and his parents, and went to Oxford to read Zoology. After a PhD with Michael Fischberg and postdoctoral work at CalTech, he returned to Oxford as an Assistant Lecturer in Zoology in 1962. John then moved to the

MRC Laboratory for Molecular Biology in Cambridge in 1971, where he became head of the Cell Biology Division before moving to the Department of Zoology and then setting up, with Ron Laskey, the CRC Unit of Molecular Embryology. In 1989 John, Ron and others founded the Wellcome/CRC Institute.

One of John’s most remarkable characteristics is that, unlike most of his peers, he continues to do experiments. He has managed to do this while being Master of Magdalene, a Governor of the Wellcome Trust and Chairman of the Wellcome/CRC Institute, with all the work and responsibilities that those positions entail, and he is an example to all of us with lesser commitments who only rarely wield the test tube!

All members of the Institute owe John a debt of gratitude for making the Institute such a success, from its establishment in 1989, to the continuing support we have received from the Wellcome Trust and the Cancer Research Campaign, and most recently for his efforts in obtaining a grant from the Wellcome Trust and the UK Government to fund our new building.

Members also appreciate John’s inclusive and democratic style of management, which has served the Institute so well in the past, and which I hope will continue to do so in the future.

John has recently become Chairman of the Board of Directors of the Company of Biologists, but we are delighted that he will stay at the Institute to continue his pioneering work on early amphibian development, and we look forward to many more years of his company, his experiments and his insightful comments.

CENTRAL SUPPORT SERVICES
Core staff provide administrative, technical and computing support to the scientists, in order to ensure the smooth running of the Institute. These vital tasks have been performed efficiently and well in 2001.

Desmond Schmidt, Computer Systems Manager, left us to return to his native Australia in August 2001. We miss both his professional skills and his dry sense of humour. His replacement, Alastair Downie, will join the Institute in January 2002.

FUNDING
During this year we learnt that our application to the Cancer Research Campaign for a further five years of core support (January 2001 to December 2005) was successful. This will therefore run alongside the core funding from the Wellcome Trust reported in last year’s Prospectus/Annual Report. Both the Wellcome Trust and the CRC (now Cancer Research UK) continue to support the Institute in the form of Fellowships, individual project grants and equipment grants.

Other sources of funding, both direct and indirect, include the European Union, BBSRC, the Royal Society, the Lister Institute of Preventative Medicine, the Elmore Trust, the Isaac Newton Trust, the Leverhulme Trust, the Association for International Cancer Research and the European Molecular Biology Organization.
Applications to HEFCE and SRIF for funding for additional vital scientific equipment for the new building have been successful.

We are extremely grateful to all these organisations for their continuing support.

**INSTITUTE FACILITIES**
The Institute has excellent facilities and these are to be supplemented, thanks to generous contributions from the Wellcome Trust and the Cancer Research Campaign, by state-of-the-art microarray facilities and by expertise in bioinformatics. These will be of great use to all the members of the Institute, and will further encourage scientific interactions between different groups.

**NEW BUILDING**
Work on our new building has now begun, and we expect it to be completed by the autumn of 2003. The building will provide enhanced laboratory and communal facilities and more core equipment space. In particular, we will be able to accommodate our improved imaging, bioinformatics, proteomic and microarray facilities. The work has caused some inevitable disruption to the lives of our neighbours in the Biochemistry Department, and we thank them for their forbearance.

**INSTITUTE RETREAT**
This year marked the tenth Institute retreat, and we celebrated the occasion by going to Amsterdam. As usual the attendance was excellent and the Retreat was a great success, both scientifically and socially.
We are studying how patterns of cell divisions and cell fates are controlled, using *C. elegans* as a model system. One aim is to understand how polarity is established in the embryo and how this information is transduced to downstream events such as spindle positioning. Control of spindle position is widespread in animal development, but little is known about the mechanisms used. We have shown that one key to this process is heterotrimeric G protein signalling. We are currently studying how the G protein is activated and how it signals to the spindle.

One approach we are taking to identifying new genes involved is genome-wide RNA interference screening. We have constructed a bacterial library for RNAi by feeding that can individually target 87% of all *C. elegans* genes. Besides being quick and easy, RNAi has the major advantage that the sequence of the gene is known for which a phenotype is found. We are studying a number of new genes involved in polarity, spindle position, and spindle orientation identified using this approach.

We are also applying genome-wide RNAi screening to understanding the role of chromatin remodelling in later patterning events. In particular, we are studying functions of the NURD chromatin remodelling complex, which regulates many patterning decisions, including those involving Ras and Wnt signalling.

Co-workers:

**YAN DONG**

**ANDREW FRASER**

**MONICA GOTA**

**RAVI KAMATH**

**NATHALIE LEBOT**

**GINO POULIN**

**MIAO-CHIH TSAI**

**CHRISTINE TURNER**

**DAVID WELCHMAN**

**PEDER ZIPPERLEN**

Posterior localisation of PAR-2::GFP (green) in wild-type *C. elegans* (above) is abolished in a new polarity mutant identified by RNAi screening (below). P granules (red) are localised to the posterior; DNA, blue.

---


For further publications, see numbers 32, 37 and 39 on pages 54 and 55.
The NURD chromatin remodelling complex is involved in many cell fate decisions. Lack of NURD function results in ectopic vulval tissue (arrows, bottom) due to inappropriate activation of the Ras pathway. Wild type (top).

A two-cell embryo with microtubules in green and centrosomes in red. The anterior cell (left) and the posterior cell (right) will divide in different orientations, specified by the positions of the centrosomes.

Many genes involved in early processes were discovered in an RNA interference screen of chromosome I. Top: series of first two cleavages in wild-type embryos. Bottom: examples of RNAi mutant phenotypes.
One of the main interests of our group is understanding the molecular events responsible for mesoderm formation and patterning. In particular, we are investigating the role of fibroblast growth factor (FGF) signalling during mesoderm formation in the frog *Xenopus laevis*. We have shown that inhibiting FGF signalling during gastrulation disrupts mesoderm formation and morphogenesis. In order to better understand this process, we have begun to isolate down-stream targets of FGF signalling. One target we have identified is the gene *Xsprouty2*. This gene has the interesting property that it is both a target of FGF signalling and a modulator of FGF signalling. Our work suggests that, by having these two properties, *Xsprouty2* co-ordinates the cell movements of gastrulation.

We are also studying how mesoderm pattern is established in the amphibian embryo by investigating the transcriptional regulation of two early mesodermal genes in transgenic embryos. One of these genes, *Xnot*, is expressed in dorsal mesoderm fated to become notochord. The other gene, *XMyf-5*, is a myogenic gene expressed in dorso-lateral mesoderm fated to become muscle.

Another focus in our group is the role of growth factor signalling in patterning of the nervous system and morphogenesis of the heart. We are generating transgenic embryos that aberrantly express genes that upregulate or downregulate growth factor signalling molecules specifically in these tissues. For these studies we have recently begun to use the binary Gal4-UAS mis-expression system.

Finally, we are initiating an insertional mutagenesis screen using a gene trap approach in *Xenopus tropicalis*, a diploid frog related to *Xenopus laevis*, with a view to identifying novel genes involved during development.


For further publications, see numbers 14 and 72 on pages 53 and 57.
A. Schematic diagram showing GAL4 activator and UAS effector constructs.
B. F1 progeny from a UASGFP effector line were injected into one cell at the two-cell stage with 100pg of Gal4 mRNA. The embryo on the right inherited the UASGFP transgene and is fluorescent due to transactivation by Gal4 (arrow). The embryo on the left failed to inherit the UASGFP transgene and therefore is not fluorescent even though it was injected with Gal4 mRNA (arrow).

Mating between a CMVGal4 line and a UASXvent-2 line results in a headless phenotype at stage 30. Xvent-2 is a transcription factor which is a direct target of BMP4 signalling. In situ hybridisation to anterior neural markers (A, B, C, D) show that the microcephalic embryos lack brain structures. They also fail to develop a notochord (F), but are able to develop muscle (E). Each panel shows a normal (upper) and microcephalic (lower) embryo.
My group is interested in how cellular diversity is generated in the nervous system, and in the signalling pathways that direct axon pathfinding. In the *Drosophila* central nervous system, neurons and glia arise from neural progenitors called neuroblasts. As they divide, neuroblasts renew themselves in a stem cell fashion and generate a series of daughter cells called GMCs. GMCs divide only once to produce two post-mitotic neurons. Neuroblasts and GMCs differ with respect to size, mitotic potential and developmental fate. A simple way to generate these two different cell types is through the asymmetric segregation of cell fate determinants. At each division the cell fate determinants Prospero and Numb are segregated from the neuroblast to its daughter.

We are studying the molecular mechanisms that direct asymmetric cell division in the nervous system, and the role of microtubules and the actin cytoskeleton in this process. We have shown that the adapter protein, Miranda, is required to segregate not only Prospero protein, but also its mRNA. Recently we have shown that myosins, motor proteins that interact with the actin cytoskeleton, play an integral role in asymmetric localisation of determinants in the nervous system. We use time lapse confocal microscopy to follow asymmetric cell division in living embryos, and have fused different spectral variants of GFP to Miranda, Prospero, Myosin, actin and microtubules for double labelling \textit{in vivo}.

We are also characterising the role in axon pathfinding of the *Drosophila* Ephrin and Fer homologues, using classical and reverse genetic approaches such as ectopic expression and targeted RNAi to eliminate expression in specific cells.


For further publications, see number 53 on page 56.
In the *Drosophila* embryonic CNS, interneuronal axons run along the longitudinal tracts (yellow; double labelled with anti Fasciclin II, green, and phalloidin, red) while the axons of motor neurons (green; anti Fasciclin II) exit the CNS to synapse on specific muscles (red; phalloidin).

Cell fate determinants (green/yellow) are asymmetrically segregated from neuroblasts to their daughters in the early embryonic CNS (DNA labelled in blue, actin in red).

Live imaging of the RP2 motor neuron as it extends its axon out of the CNS towards its target muscle.

Please see Brand lab home page:
http://www.welc.cam.ac.uk/~brandlab/
Cellular adhesion and communication are vital during the development of multicellular organisms. These processes use proteins on the surface of cells, which stick cells together or transmit signals from outside the cell to the interior, so that the cell can respond to its environment. Members of one family of cell surface receptors, called integrins, can perform both of these activities and therefore provide a molecular link between cell adhesion and signalling. Our research is focused on determining how proteins inside the cell assist the integrins in their developmental roles: mediating cell migration, adhesion between cell layers and cell differentiation.

To discover what other proteins are required to work with the integrins, we have used the genetics of the fruit fly *Drosophila* to identify genes required for integrin-mediated adhesion. The molecular characterisation of these genes is providing a description of the proteins that make up the structure that links the integrins to the cytoskeleton. These proteins include the cytoskeletal linker proteins kakapo and talin, and the signalling adaptor proteins integrin-linked kinase and tensin. By manipulating the structure of these proteins and assaying their function in the living animal we are elucidating how they contribute to integrin mediated adhesion during development. Recent work has shown that some of these components also contribute to the formation or regulation of cell–cell junctions formed by other types of receptor, thus connecting the different kinds of cell adhesion performed by the cell.

Co-workers:

CHRISTIAN BÖKEL
DANELLE DEVENPORT
MARCUS HICKS
MAITHREYI
NARASIMHA
JOHN OVERTON
KATJA RÖPER
CATHY TORGLER
VIKKI WILLIAMS
CHRISTOS ZERVAS


For further publications, see number 13 on page 53.
Attachment of actin (red) to the ends of the muscles is reduced to a few strands when the sequence of integrin-linked kinase (green) is altered.

Maintaining an even distribution of cell–cell junctions (red) requires intracellular signalling (the cells that lack the green marker are defective in signalling).

Integrin based adhesion junctions (shown with tensin in orange) link together microtubule transalar arrays (blue) in the developing wing. The apical surface of each cell layer is visible from autofluorescence (darker orange).
Our group is interested in nuclear reprogramming and cell fate determination by signal factors in amphibian development. The transplantation of a nucleus from specialised tissue such as the intestine to an enucleated egg generates embryos in which the expression of intestine-specific genes has been rapidly extinguished and that of early embryo genes activated. However, the expression of individual early zygotic genes in single nuclear transplant embryos (that is, in cells derived from the transplantation of a single intestine nucleus) is incorrectly and variably regulated. Nevertheless, cells from such embryos can differentiate into many tissue types, such as muscle, unrelated to the donor cell type (intestine).

Embryonic cells can be made to embark on diverse cell differentiation pathways by exposure to the appropriate concentration of a signal factor such as activin. Factors that work in this way are called morphogens, and are widely operative in development. We have determined the number of occupied receptors, the rapidity of intracellular Smad2 phosphorylation, and the real-time migration of GFP-Smad2 to the nucleus. We conclude that, as a morphogen gradient changes with time, cells adjust the volume but not rate of intracellular transduction flow. Another concentration-dependent signal process is the community effect in which we find that cells signal to each other via FGF4 to collectively form a homogeneous tissue such as muscle.

Our aim is to understand the mechanisms of nuclear reprogramming, morphogen action, and the community effect, thereby elucidating basic processes of development and contributing to the eventual success of cell replacement therapies.

For further publications, see numbers 15, 16, 40, 63 and 87 on pages 53 and 55–57.
FUNDAMENTAL MECHANISMS OF CELL FATE DETERMINATION

GFP-Smad2 in the nucleus of a blastula cell

2 hours after a 10 min activin exposure

Differentiated tissue (intestine)

Differentiated cells (muscle)

Community effect (FGF)

Competence

Morphogen concentration (activin, BMP)

Extracellular morphogen concentration

1 hr

3 hrs

Gene A

Gene B

Receptor occupancy and volume, not rate of transduction flow, increases with time

Dedifferentiation

Redifferentiation

Nuclear transfer

Nuclear reprogramming

Egg

Blastula

Mesoderm

Graft of tissue from nuclear transplant embryo
To maintain genomic integrity, eukaryotic cells have developed elaborate, highly conserved pathways to detect, signal and repair DNA damage. One of our particular interests is DNA double-strand breaks and their repair by non-homologous end joining (NHEJ). In NHEJ, DNA damage is detected by the Ku heterodimer, part of DNA-dependent protein kinase (DNA-PK). Binding of Ku to DNA ends allows the efficient binding of DNA-PK’s catalytic subunit to the break and the subsequent recruitment of other factors needed for efficient DNA damage repair, including a complex comprising two molecules of Xrcc4 and one DNA ligase IV molecule. In a recent collaboration, we determined the structure of this complex (Fig. 1).

We are also investigating the role that some components of the NHEJ apparatus play in telomere maintenance, another process essential for genome stability. Thus, we have found that inactivation of Ku in mice leads to telomere shortening and the appearance of dramatic chromosomal abnormalities (Fig. 2).

Finally, we are investigating DNA damage-induced checkpoints. These key responses to DNA damage, which are highly conserved between yeast and man, halt the cell cycle to allow time for DNA repair before genome replication and cell division occur. We have recently found that the yeast Xrs2p/Rad50p/Mre11p complex is important in checkpoint signalling (Fig. 3). This result provides insights into the mechanism of checkpoint activation in both yeast and human cells, where the orthologous NBS1/RAD50/MRE11 complex forms part of the medically important ATM DNA damage signalling pathway.


For further publications, see numbers 7–9, 22, 27, 28, 30, 34, 44, 50, 54 and 94 on pages 53–56 and 58.
Fig. 2. Telomeres are structures at chromosome ends that contribute to chromosomal stability. The figure shows examples of chromosomal abnormalities in mice lacking Ku. A shows a ring-like structure; B is a dicentric chromosome; C and D show chromosomes with gaps or chromatid breaks. For comparison, E shows a representative normal metaphase chromosome. The chromosomes have been hybridised to a telomeric probe (yellow) and the DNA stained with DAPI (blue). Collaboration with M. P. Hande (Columbia University, NY, USA).

Fig. 3. This figure shows a working model for how the yeast Xrs2p/Rad50p/Mre11p complex might be involved in checkpoint signalling. In this model, production of a DNA double-strand break (DSB) by ionising radiation or radiomimetic agents is detected and processed by the nuclease activity of Mre11p. Next, the single-stranded DNA ends activate Tel1p and/or Mec1p, checkpoint kinases that are the yeast homologues of mammalian ATM and ATR, respectively. Finally, the activated kinases phosphorylate Xrs2p, Mre11p and other factors, and checkpoint arrest is stimulated.
Many transcriptional regulators are de-regulated in cancer. Our group is interested in defining the mechanisms by which such transcription factors function during normal cell proliferation and in cancer.

Our attention is focused on a set of enzymes which modify histones and regulate transcription via chromatin remodelling. We would like to understand how, mechanistically, these modifications affect transcription, the biological role of histone modifying enzymes and their potential involvement in cancer.

Recently, we have focused on the process of histone methylation, which can occur on specific lysine or arginine residues. We have extensively studied the methylation of lysine 9 of histone H3. This methylation leads to the transcriptional silencing of genes found in heterochromatin and of cell cycle genes regulated by the retinoblastoma (RB) repressor. Lysine 9 methylation mediates silencing by recruiting the repressor protein HP1.

In contrast to methylation of lysine 9, methylation of lysine 4 on histone H3 is activatory for transcription. We have identified the enzymes in yeast that mediate methylation at lysine 4 and are now characterising their mammalian equivalents. We can show that lysine 4 methylation prevents the association of histones with deacetylases, a process which would otherwise lead to repression.

A distinct set of enzymes methylates arginines. We have characterised one such methylase, CARM1, which is a regulator of nuclear hormone receptors. Our data show that CARM1 methylates arginine 17 of histone H3 in vivo and that this modification is deposited on histones when estrogen receptor-regulated genes are active.

Differentiation of myoblasts (top) into myotubes (bottom) induces translocation of GFP-HDAC4 from the cytoplasm to the nucleus.
Model of RB-mediated repression of the cyclin E gene. RB recruits methylase activity specific for lysine 9 of histone H3 to the promoter. This methylation is then recognised by the HP1 repressor protein.

The pattern of modifications on histone tails differs on active and repressed genes. The differentially modified histones are also associated with a distinct set of proteins.
Mitotic neural stem and progenitor cells integrate extracellular and intracellular information in each cell cycle to decide the fates of their progeny. This is a fundamental cellular process, common to all tissues in the organism, and depends to a large extent on the dynamic use of the available genes in the genome. Our lab uses genomics technologies to understand how the genome is deployed during this decision-making process. The goal is to identify the genetic networks that control cell fate determination.

During development, different neurons are generated in a stereotyped order from the available pool of dividing stem and progenitor cells. One important mechanism that controls which cells are generated at a given time is the competence of stem and progenitor cells to generate particular cell types in response to extracellular signals. Progenitor competence changes over time, and this is a fundamental way in which the stereotyped order of genesis of cell types is achieved. However, little is known about the cellular mechanisms controlling progenitor competence, how they interact with the processes controlling cell cycle exit and cell fate determination, and how competence changes over time.

The lab investigates the intrinsic control of progenitor competence and neural cell fate determination using the mouse neocortex as a model system. The ordered genesis of the six cellular layers of the neocortex is achieved in part by temporal changes in the competence of cortical progenitors. We are using expression profiling of neural progenitors and their progeny to identify gene expression networks involved in regulating competence and laminar (cell layer) cell fate determination in the neocortex. Although composed of the same six layers in all areas, the neocortex has discrete areas primarily dedicated to, for example, motor control, the somatic senses, vision and hearing. Therefore, a second area of research is how the basic processes of cell fate determination in the neocortex are adapted and used to generate the different functional areas.

Facing page: Gene expression profiling of single neural progenitors using cDNA microarrays. cDNA amplified from a single progenitor cell (red) was compared with that of total brain (green) to identify progenitor-enriched transcripts on an array of over 12,000 mouse genes from the NIH Brain Molecular Anatomy Project (BMAP) — progenitor genes appear as bright red spots.

Right: Characterising the gene expression program of mammalian neural progenitors and stem cells. Gene expression in purified populations of retinal progenitors was compared to that in total brain using cDNA microarrays of over 12,000 genes. The resulting data were analysed by several different forms of cluster analysis, a method of exploratory statistics, two of which are shown here. The graphs show part of the results of k-means clustering of the data, and the colour blocks the results of hierarchical clustering. In both cases, three classes of progenitor-enriched genes are shown, depending on their enrichment compared to total brain and retina. Overall, we have identified several hundred genes that are highly enriched in their expression in neural progenitors in all parts of the nervous system.

Examples of progenitor-enriched genes. In situ hybridisation showing expression of two progenitor-enriched genes in the developing neural retina.
Our research focuses on mouse primordial germ cells and the pluripotent stem cells derived from them.

We have established that prenatal entry into meiosis, the prelude to oogenesis, occurs spontaneously in both XX and XY germ cells, but is inhibited in the male genital ridge. In a search for the molecular basis of this masculinising influence, one of the genes that we have identified is prostaglandin D synthase. Prostaglandin D₂, a signalling molecule, is expressed in both germ cells and supporting cells in the male genital ridge, possibly generating a masculinising feedback loop. We are now investigating some of the other genes that have come out of our screening programme. In a different series of experiments, we are exploring the genetic basis of entry into meiosis in the female genital ridge.

Using the embryonic germ (EG) cell lines that we have derived from primordial germ cells both during migration and after reaching the genital ridge, we are now comparing the methylation status of imprinted genes in EG cells with that of their progenitor cells, as a measure of imprint erasure. Some imprinted genes show sex differences in the degree of hypomethylation in EG cells: using sex-reversed embryos we are exploring whether these differences reflect genotypic or phenotypic sex.

We are also interested in the effect of culture conditions on cell differentiation, for example the duration of exposure to culture that is required to shift the germ-cell to the stem-cell phenotype, and the subsequent possibilities for directed differentiation of the pluripotent stem cells.


For further publications see numbers 66 and 70 on pages 56 and 57.
Primordial germ cells (PGCs) were isolated from male (♂) or female (♀) donor urogenital ridges (UGR), mixed with male or female 12.5 dpc recipient UGRs and cultured. Donor PGCs are marked with a cyan perinuclear dot (LacZ+). Meiotic oocytes (arrowheads) have condensed chromatin staining. Arrested prospermatogonia (arrows) have diffuse chromatin staining with prominent nucleoli. At 11.5 dpc PGCs are sexually bipotential and develop as male or female, depending on the sex of the surrounding cells. By 13.5 dpc PGCs have become committed to develop as either oocytes or prospermatogonia and continue to develop along that pathway, regardless of the sex of the surrounding cells.

Primordial germ cells carrying a LacZ transgene are converted, after short culture, into pluripotent stem cells. These cells showed low (A) and high (B) level of contribution to chimeras. Cells preferentially colonised the lungs (lu), heart (h), and liver (li). At later stages, skeletal abnormalities are evident in a few of these chimeras. A fetal chimera with a normal skeleton is shown in (C) and one with skeletal defects is shown in (D).
During embryonic development, neuroectodermal cells exit the cell cycle and differentiate in a stereotypical spatial and temporal pattern. The spatial and temporal control of neurogenesis is important for regulating cell type specification and the final number of differentiated cells. To understand how this control is achieved, we use the frogs *Xenopus laevis* and *Xenopus tropicalis* as model systems and a combination of molecular and classical embryology.

At the onset of neuronal differentiation, the neural ectoderm expresses a number of highly localised transcription factors. We are aiming to understand how these transcription factors instruct subsets of cells to differentiate and others to continue dividing. Our recent work focused on the interaction of a telencephalic transcription factor, XBF-1, and components of the cell cycle. While research on this front is continuing, we are working to identify additional genes in this pathway as well as novel genes that affect neural development.

Recently, we have discovered that the early neural ectoderm is not a homogeneous population of progenitor cells. Instead it contains progenitor cells with intrinsically different capacities for differentiation. As a result, a subset of neuronal progenitor cells do not differentiate in response to the inducing signals present in the early embryo and continue to divide instead. This intrinsic difference is likely to result from asymmetric cell divisions that take place at the blastula stage. Nucleic acid and protein screening projects are under way to identify the determinants involved in this process.

Co-workers:

**SAMANTHA CARRUTHERS**  
**ANDREW CHALMERS**  
**PENNY DAY**  
**ELENA FINEBERG**  
**SUE KENWRICK**  
**BERNHARD STRAUSS**  
**MARGARET TYCE-BUTCHER**  
**JANA VOIGT**

A pooled cDNA expression screen is used to identify molecules that affect neurogenesis. In this example, a single identified clone inhibited differentiation on the injected side (Jana Voigt).


At the 16-cell stage, spindles are parallel to the surface of the embryo. At the late blastula stage, spindles are either parallel or perpendicular to the surface of the embryo, generating cells with different intrinsic properties. Just before gastrulation, all spindles are once again oriented parallel to the surface (Andrew Chalmers and Bernhard Strauss).

Knocking out the cell cycle inhibitor p27 Xic by an antisense morpholino oligo inhibits neuronal differentiation (Samantha Carruthers).

Implantation of BMP4 protein soaked beads (blue) into experimental + GFP RNA injected region (green) shows the co-operation of two signalling pathways in inducing a neural border marker gene (Penny Day).
We are studying how cells control their division and are following two parallel approaches to this question. In one we are concentrating on how the proteins that trigger the entry into mitosis are regulated by their subcellular localisation. These proteins, such as the cyclins, the CDKs and the Cdc25 phosphatases, alter their localisation as cells progress through the cell cycle. Therefore, particular proteins can only interact with each other in specific places and at specific times. We are able to assay this behaviour in real time by time-lapse fluorescence and DIC video microscopy using GFP-fusion proteins. We use this assay to define the domains of the proteins that target them to specific subcellular structures, and to determine how their localisation is altered depending on the stage of the cell cycle. After defining these domains we use them to isolate the proteins that are responsible for targeting and controlling the subcellular location of mitotic regulators.

Our second avenue of research is directed towards understanding how proteolysis is used to regulate progress through mitosis. Again we are able to assay this in real time using GFP-fusion proteins because fluorescence is directly related to the amount of a GFP-fusion protein. We are investigating the behaviour of key substrates at each stage of mitosis, including cyclin A, cyclin B1 and securin, and are using these to define the events and the mechanisms that trigger the destruction of specific proteins at specific times and in specific places.


For further publications, see numbers 55, 68, 75, 78 and 100 on page 56–58.
Cyclin B1-degradation visualised in real time. Cyclin B1–GFP purified from baculovirus-infected cells was injected into a HeLa cell and then imaged with a cooled slow-scan CCD camera. Left panels: DIC images; middle panels: fluorescence; right panels: merged images.

HeLa cells expressing Cdc20-GFP in metaphase (top) and anaphase (bottom). The images on the left are derived by deconvolution from those on the right.

HeLa cells in anaphase (top) and prometaphase (bottom) stained for anti-phospho-histone H3 (green), anti-CENP-E (red) and CREST anti-centromere antibodies (blue).
The centrosome is the main microtubule organising centre in animal cells. Despite their central role in organising many cellular events, very little is known about how centrosomes function. We have taken a reductionist approach to this problem, using Drosophila as a model system to isolate proteins that bind to microtubules in vitro and associate with centrosomes in vivo. One of these proteins, called D-TACC, interacts with microtubules in association with Minispindles, the Drosophila homologue of XMAP215, a well characterised microtubule stabilising protein that is also concentrated at centrosomes. The interaction between D-TACC and Msps appears to play a crucial role in regulating the stability of centrosomal microtubules in embryos. The interaction between D-TACC and Msps is conserved in evolution, and the human homologues of both D-TACC and Msps have previously been implicated in cancer. We are currently using double-stranded RNA-mediated interference (RNAi) to probe the function of these proteins in human cells.

Many cell cycle regulators are associated with centrosomes and we have started to analyse the potential role of the centrosome in regulating cell cycle events. We have shown that the degradation of cyclin B is spatially regulated within cells. Our observations suggest that centrosomes are required to initiate the destruction of cyclin B in Drosophila embryos, and we are currently investigating how this might be regulated at the molecular level. We have shown that the Drosophila anaphase promoting complex (APC) is not strongly concentrated at centrosomes, but that two regulators of the APC (fzy and fzr) are concentrated at centrosomes.

Co-workers:
RENATO BASTO
SUE CROYSDALE
ANNEGRET FINLAY
FANNI GERGELY
JUNYONG HUANG
MICHAEL LEE
MARUXA MARTINEZ
CHODAGAM SASIDHAR


For further publications, see numbers 36 and 82 on pages 55 and 57.
The distribution of DNA (red), microtubules (green) and centrosomes (blue) in normal (top panels) and D-TACC mutant (bottom panels) embryos. In the mutant embryos, the microtubules associated with the centrosomes are too short at all stages of the cell cycle.

The distribution of the three known human TACC proteins (TACC1, TACC2 and TACC3) in human cells. The TACC proteins are shown in red and microtubules in green in the merged image.
The localisation of *bicoid*, *oskar* and *gurken* mRNAs to three distinct positions within the *Drosophila* oocyte defines the anterior-posterior and dorsal-ventral axes of the embryo, and provides an excellent model system for analysing the molecular mechanisms that underlie cell polarity and mRNA localisation. My group is taking a variety of approaches to address these issues:

1) The dsRNA-binding protein Staufen is required for the microtubule-dependent localisation of *bicoid* and *oskar* mRNAs, and for the actin-dependent localisation of *prospero* mRNA to the basal side of dividing neuroblasts. We are currently characterising proteins that interact with Staufen to mediate mRNA transport along actin or microtubules. Since Staufen co-localises with each mRNA, we are also using GFP-Staufen to visualise mRNA transport *in vivo*.

2) The PAR-1 kinase is required for posterior localisation of *oskar* mRNA, and provides the first example of a protein that plays a conserved role in axis formation in *Drosophila* and *C. elegans*. We are now analysing the role of PAR-1 in polarising other cell types in *Drosophila* and are searching for its targets.

3) Since many proteins involved in mRNA transport or cell polarity are required throughout development, they were not identified in the classical genetic screens for maternal-effect mutations that disrupt axis formation. To overcome this problem, we are performing large-scale screens in germline clones for mutants that affect GFP-Staufen localisation. We have already identified a number of novel genes that are required for the polarisation of the oocyte or for the localisation of *bicoid* or *oskar* mRNA, and are now analysing their functions.

Selection of the oocyte as a *Drosophila* germline cyst moves through the germarium. Several cells per cyst initially enter meiosis and form the synaptonemal complex (red), before one cell is selected to remain in meiosis and accumulates oocyte-specific proteins such as Orb (green).
mRNA LOCALISATION AND THE ORIGIN OF POLARITY IN DROSOPHILA

The localisation of bicoid mRNA (black) and oskar mRNA (red) to opposite poles of the oocyte at stage 10.

NMR structure of one double-stranded RNA binding domain from Staufen protein (red) bound to a 12bp RNA stem-loop (blue). The amino acid side chains that contact the RNA are shown in yellow. Collaboration with Andres Ramos and Gabrielle Varani (LMB-MRC).

A fused egg chamber with two oocytes of opposite polarity, marked with GFP-Staufen (green), Fascilin III (red) and a nuclear stain (blue). The fusion was caused by a follicle cell clone of agro, a novel component of the Notch pathway.
Our research addresses the mechanisms by which the mesoderm of the vertebrate embryo is formed. Most of the work involves use of the amphibian species *Xenopus laevis* and *Xenopus tropicalis*, but we also make use of zebrafish embryos when appropriate. We are interested in studying mesoderm-inducing signals, such as the nodal-related genes and derrière, in the signal transduction pathways used by these factors (especially the Smad proteins), and in the genes that are activated as immediate-early responses to induction. Transgenic *Xenopus* embryos are used to study how these immediate-early genes are regulated and to identify their targets. We also study the regulation of the cell cycle in the mesoderm and we make extensive use of morpholino anti-sense oligonucleotides to block gene function, both in *Xenopus laevis* and in the diploid species *Xenopus tropicalis*.

Much of our work concentrates on the T box gene family, and especially *Brachyury*, which responds to mesoderm-inducing factors in a strict dose-dependent fashion and which, when mis-expressed, can cause prospective ectodermal cells to form mesoderm. *Brachyury* is also required for the morphogenetic movements of gastrulation, and we have identified *Wnt11* as a target of *Brachyury* that is required for gastrulation movements in both *Xenopus* and zebrafish. *Wnt11* signals through the planar polarity pathway, and we are investigating the roles of *Wnt11* and components of the planar polarity pathway in gastrulation using cell biological and imaging techniques. We are also investigating the functions of other T box targets such as members of the Bix family of homeodomain-containing proteins.

Co-workers:
- Niall Armes
- Julia Bate
- Kevin Dingwell
- Donna Grimmer
- Christin Kabitschke
- Dunja Knapp
- Sara Mercurio
- Nigel Messenger
- Olaf Piepenburg
- Yasushi Saka
- David Simpson
- Shankar Srinivas
- Nicola Tavener
- Fiona Wardle
- Richard White
- Huw Williams


For further publications, see numbers 23, 77, 83, 89, 90 and 97 on pages 54, 57 and 58.
Expression of Xbra (left) and SIP1 (right) at the late gastrula stage. The two expression domains are mutually exclusive.

Xenopus animal pole regions adhere strongly to fibronectin, allowing clear visualisation of cells in the confocal microscope. In this image, two animal caps, one of which is labelled with a membrane marker, are juxtaposed.

Specificity of T box genes in the early Xenopus embryo. Xbra, VegT and Eomesoderm are expressed in similar domains, but they activate the expression of different genes.
We are investigating the origin of the mouse germ cell lineage, together with some of the epigenetic modifications that are unique to this lineage. Germ cells develop from the proximal epiblast cells in response to the signalling molecules from extraembryonic tissues (Fig. 1). These precursor cells are not lineage restricted as they can develop either into primordial germ cells or somatic cells, including the allantois. We have established a genetic screen using single cell cDNAs, which has identified novel genes involved in the specification of the 45 founder primordial germ cells in E7.5 embryos. Some of the novel genes may also have a role in pluripotent embryonic stem cells (ES) and embryonic germ (EG) cells (Fig. 2).

After the germ cells begin to migrate into the developing gonads at E10.5, epigenetic modifications unique to this lineage follow, perhaps in response to signal(s) from somatic cells. Reprogramming and erasure of epigenetic modifications within germ cells includes reactivation of the X chromosome, erasure of genomic imprints and genome-wide demethylation (Fig. 3). We are investigating the identity of the intrinsic factors involved in this reprogramming event. We are also exploring the mechanisms by which epigenetic states can be reversed to confer pluripotency to differentiated somatic cells.

New imprints are initiated during gametogenesis that require cis control elements associated with imprinted genes (Fig. 3). Mature oocytes contain factors, including HP1 and Ezh(2), that regulate, enhance and maintain the epigenetic asymmetry between parental genomes in early embryos. The imprints are heritable from the zygote into adulthood where they regulate expression of imprinted genes serving diverse functions, including growth, differentiation and behaviour.


For further publications, see numbers 2, 5, 25, 45, 50–52, 69 and 74 on pages 53–57.
**Fig. 1** (above). The proximal epiblast cells on day 6.0 p.c are the precursor cells for the germ cell lineage. They converge towards the posterior region where the primitive streak develops. These precursor cells develop either as germ cells or as somatic extraembryonic mesoderm. Approximately 40 founder primordial germ cells (PGCs) are detected at day 7.2 p.c. Development of PGCs is dependent on signalling molecules from the extraembryonic ectoderm, and possibly on a second signal from the posterior region whose nature and origin is unknown.

**3A** Germ cells in fetal gonads at day 12.5 p.c.

- Female
- Male

*Erasure of imprints
*Demethylation

**Fig. 3** (right). A. Germ cells migrate into the fetal gonads by day 12.5 p.c, shown here as expressing Oct4-GFP, during which time major epigenetic modifications occur. Erasure of imprints is followed by the initiation of new imprints that are propagated after fertilisation. In the female germ line, imprinting is initiated in the growing oocytes. B. A cis control element (DMD) associated with the H19 gene that confers silencing of the paternal allele. Deletion of SL also results in de-repression of the silent paternal allele.

**3B** Imprinting cis control element

Initiation of imprints

Oogenesis
Spermatogenesis

Pre-implantation development propagation of imprints
We are studying how polarity and patterning becomes established during early mouse development. Whereas in most species the polarity of the embryo is laid down in the egg, mammalian embryos were thought to be exceptional, their polarity apparently developing only after implantation. However, our recent cell fate studies showed that mouse embryo polarity is anticipated before implantation and relates to spatial patterning of the egg. This was unexpected because preimplantation embryos can withstand experimental perturbations and still develop normally. Now we wish to understand those mechanisms that establish polarity in normal development and those that compensate for developmental perturbation. Specification of polarity appears to stem from the position of the meiotic divisions in the egg and the site of sperm entry. The pattern of cell division is influenced by these cues and can dictate the basic features of blastocyst organisation and hence of later stages. These surprising findings open several questions about the origin of polarity in mammals.

We address the following:

1) How do developmental cues lead to asymmetry? We are combining experimental and molecular embryology to disturb egg polarity and examine its role in early patterning.

2) How does polarity of the preimplantation embryo lead to organised signalling activity at later developmental stages? We are using lineage and transplantation studies to examine the normal fate of cells and their impact in novel combinations.

3) What are the mechanisms that establish polarity? We are applying microarray analysis to discover genes that mediate the development of polarity and then perturbing spatial and temporal patterns of expression of such genes through mis-expression and RNAi.

Co-workers:
STEPHEN FRANKENBERG
DANIEL MESNARD
CATHERINE MOORE
KAROLINA PIOTROWSKA
BERENIKA PLUSA
BEDRA SHARIF
FLORENCE WIANNY


For further publications, see numbers 80, 81, and 100 on pages 57 and 58.
Preimplantation development of the mouse embryo. Fertilised egg with female and male pronuclei (pink and blue stars, respectively) and polar body marking the animal pole (red asterisk). Blastocyst with its animal-vegetal (yellow) and embryonic-abembryonic (blue) axes.

Blastomeres of the 2-cell mouse embryo have distinguishable fates. The fertilisation cone (fc) with sperm tail (yellow) and fluorescent bead (green) marks the sperm entry point (SEP) in the zygote. The 2-cell blastomere that inherits the SEP (red) tends to divide first to produce cells that populate the embryonic part of the blastocyst. The other blastomere (blue) tends to populate the abembryonic part of the blastocyst.

Polarity of the blastocyst anticipates polarity of the post-implantation embryo. Microinjection of GFP mRNA into inner cell mass cells either near (N/PB) or away (A/PB) from the polar body demonstrates differential fate in the post-implantation egg cylinder.
A major issue in developmental biology is how the embryo subdivides into progressively smaller regions, each with a unique identity. This project concerns the mechanism by which two such regions are specified: the notochord and the pineal gland. The earliest known transcription factor expressed by these tissues is encoded by the *not/flh* gene. Zebrafish harbouring mutations in this gene fail to form either tissue indicating that the gene functions at or near the top of a hierarchy specifying their development. In order to identify the direct regulators of the *not/flh* gene we are using transgenesis in *Xenopus*. We have also prepared a transgenic line of animals expressing GFP under the control of the *flh* regulatory elements. These animals are being used to study the development and neural networking of the pineal gland, which in *Xenopus* functions as a light sensor mediating early behavioural responses to environmental stimuli.

**Co-worker:** KIM GOLDSTONE

**KIM GOLDSTONE**

Intracellular localisation of messenger RNA (mRNA) is a common way of targeting proteins to the regions where they are required. One of the best characterised examples of localised mRNA is found in the *Drosophila* oocyte, where the microtubule-dependent localisation of *oskar* mRNA to the posterior pole of the oocyte specifies the formation of the pole plasm. Genetic screens have identified genes that are required for the localisation of *oskar* mRNA. These genes can be compiled into two categories: Those that are required for cell polarity and those that are specifically required for the transport of *oskar* mRNA, such as staufen, mago nashi, barentsz and kinesin. The aim of my research is to understand the mechanism of *oskar* mRNA localisation by analysing the precise function of those factors. I am taking several approaches to address this question: 1) I am using GFP-Staufen to visualise mRNA transport *in vivo*; 2) I am searching for new proteins that interact with Mago nashi and Barentsz; and 3) I am studying how Kinesin, a microtubule motor protein, recognises the *oskar* mRNA-containing complex and localises it to the posterior pole of the oocyte.

For recent publications, see numbers 29, 76 and 96 on pages 54, 57 and 58.
Our research focuses on the molecular mechanisms underlying the formation of organs such as the liver, pancreas and lungs. In vertebrate embryos, naïve endoderm is patterned by a complex and poorly understood series of tissue interactions. As a result some endodermal cells are induced to form the liver while others give rise to the pancreas or lungs. Using the frog embryo as a model, we are applying a combination of molecular and embryological techniques, including microarray technology and transgenics, to uncover the molecular and cellular events responsible for early liver development. Current investigations examine how transcription factors integrate signals from different growth factors to specify endoderm and embryonic liver. We are also conducting a number of screens to find novel genes involved in liver organogenesis.

For recent publications, see numbers 15, 87, 91 and 103 on pages 53, 57 and 58.
CATEGORIES OF APPOINTMENT

Senior Group Leader
Professor, Reader or Lecturer Level

Group Leader
Five-year grant-funded appointment (maximum 10 years)

Career Development Fellow
Four-year grant-funded appointment, within individual groups

Independent Senior Research Associate
Three-year grant-funded appointment, within individual groups

Research Associate/Fellow
Postdoctoral, within individual groups, appointed by group leader

Graduate Student
Three-year studentship within individual groups, mainly grant-funded

Research Assistant
Postgraduate, within individual groups, mainly grant-funded

Research Technician
Within individual groups, mainly grant-funded

Laboratory Assistant
Within individual groups or part of core support, grant-funded

POSTGRADUATE OPPORTUNITIES

As part of the University of Cambridge, the Institute welcomes enquiries from prospective graduate students. We have a thriving population of graduates who contribute greatly, not only to the stimulating research environment, but also to the life of the Institute as a whole. Additionally, graduates become members of the biological or medical sciences department to which their group is affiliated. Graduate studentships are supported mainly by the Wellcome Trust or Cancer Research UK but additional sponsorship may be solicited from a variety of sources, including government research councils. Applicants should write, in the first instance, to the leader of the group they wish to join.
SHANKAR SRINIVAS PhD
   HFSP Fellow
NICOLA TAVERNER BSc
   Wellcome Graduate Student
FIONA WARDLE PhD
   Wellcome Research Associate
RICHARD WHITE MA
   MRC Research Assistant
HUW WILLIAMS BSc
   Wellcome Prize Student

OLIVER GRIMM Dipl Biol
   Böhringer Ingelheim Graduate Student
JULIA MASON BSc
   Wellcome Research Assistant
TIMOTHY ROBINSON BSc
   Magdalene College Manifold Graduate Student
KAZUYA SHIMIZU PhD
   Cancer Research UK Research Associate
STINA SIMONSSON PhD
   BBSRC Research Associate
HENRIETTA STANDLEY BA
   Cancer Research UK Graduate Student
ELIZABETH TWEED
   Cancer Research UK Research Technician
CAROLINE WEBB
   Personal Assistant
JOOST WOLTERING
   Dutch Undergraduate Project Student
AARON ZORN PhD
   Wellcome Career Development Fellow

JOHN GURDON Kt DPhil DSc FRS
Distinguished Group Leader
Foreign Associate, US National Academy of Sciences
Member, European Molecular Biology Organization
Member, Academia Europaea
(Affiliated to Department of Zoology)

PIERRE-YVES BOURILLOT PhD
   Wellcome Research Associate
KAREN BUTLER BSc
   Cancer Research UK Research Assistant
JAMES BYRNE BSc
   BBSRC Graduate Student
RICARDO COSTA BSc
   Portuguese FCT Graduate Student
NIGEL GARRETT MIBiol
   Wellcome Research Assistant

STEVE JACKSON PhD
Frederick James Quick Professor of Biology
Member, European Molecular Biology Organization
(Affiliated to Department of Zoology)

PETER AHNESORG BSc
   Evangelisches Studienwerk Student
MEMBERS OF THE INSTITUTE

REBECCA APPELHOFF BSc
MRC Graduate Student

STEVE BELL PhD
Wellcome Research Associate

JANE BRADBURY PhD
Cancer Research UK Senior Research Associate

FABRIZIO D’ADDA DI FAGAGNA PhD
Cancer Research UK Research Associate

DAMIEN D’AMOURS MSc
MSERC/Cancer Research UK Graduate Student

JESSICA DOWNS PhD
Cancer Research UK Research Associate

DANIEL DUROCHER PhD
Hitchings Elion Fellow of the Burroughs-Wellcome Fund

SABRINA GIAVARA BSc
Cancer Research UK Graduate Student

MICHAL GOLDBERG PhD
AICR Research Associate

SERGE GRAVEL PhD
EMBO Fellow

MURIEL GRENON PhD
Cancer Research UK Research Associate

ANNE HARVEY
Cancer Research UK Research Assistant

SEYED ALI JAZAYERI BSc
Cancer Research UK Graduate Student

NICHOLAS LAKIN PhD
AICR Research Associate

CHRISTINE MAGILL BSc
Cancer Research UK Senior Research Technician

ANDREW MCAINSH BSc
MRC Graduate Student

VENKAT PISUPATI MPhil
Cancer Research UK Research Assistant

PHILIP REAPER BSc
Cancer Research UK Graduate Student

HELEN REED
Secretary

JOHN ROUSE PhD
Cancer Research UK Research Associate

TONY KOUZARIDES PhD, F Med Sci
Royal Society Napier Professor
Member, European Molecular Biology Organization
(Affiliated to Department of Pathology)

ANDREW BANNISTER PhD
Cancer Research UK Senior Research Associate

UTA-MARIA BAUER PhD
Cancer Research UK Research Associate

WENDY BURGERS MSc
FRD Scholarship/St John’s College Graduate Student

ALISTAIR COOK GIBiol
Cancer Research UK Chief Research Technician

SYLVAIN DAJJAT PhD
Cancer Research UK Research Associate

RAJAT ROY MSc
Nehru Scholarship Graduate Student

JO SLATOR BSc
Cancer Research UK Chief Research Technician

DONNA SMITH
Clerical Assistant

VERONIQUE SMITS PhD
Cancer Research UK Research Associate

MANUEL STUCKI PhD
Swiss Government Fellow

SOO-HWANG TEO PhD
Royal Society Dorothy Hodgkin Fellow

BRANDI WILLIAMS PhD
HFSP Long-Term Fellow

SENIOR GROUP LEADERS
MEMBERS OF THE INSTITUTE

FRANÇOIS FUKS PhD
Wiener-Anspach Fellow

LUKE HUGHES-DAVIES PhD
Cancer Research UK Clinician Associate, affiliated to Department of Oncology

PAUL HURD PhD
Cancer Research UK Research Associate

EMMA LANGLEY PhD
Cancer Research UK Research Associate

MORVEN REID BSc
Cancer Research UK Graduate Student

PATRICIA RENDLE
Secretary

MARGARIDA RUAS PhD
Cancer Research UK Research Associate

STEVEN SANDERS PhD
Cancer Research UK Research Associate

HELENA SANTOS ROSA PhD
EU Fellow

ROBERT SCHNEIDER PhD
EMBO Fellow

DANIEL WOLF MBioch
Wildy Graduate Student

PHILIP ZEGERMAN BA
Cancer Research UK Graduate Student

RON LASKEY DPhil FRS F Med Sci
Charles Darwin Professor of Animal Embryology
Member, European Molecular Biology Organization
Member, Academia Europaea
(Affiliated to Department of Zoology)

MAGDALENA ASSENBERG MSc
Cancer Research UK Graduate Student

DAWN COVERLEY PhD
Cancer Research UK Research Associate

GUILLERMO DE LA CUEVA MENDEZ BSc
Cancer Research UK Research Assistant

LORENA FARRACE BSc
Cancer Research UK Research Assistant

SENIOR GROUP LEADERS

CHRISTINE FOX
Secretary

TORSTEN KRUDE PhD
Royal Society Research Fellow

JACKIE MARR HNC
Cancer Research UK Senior Research Technician

TONY MILLS BEd
Cancer Research UK Research Assistant

CHRISTINA PELIZON PhD
HFSP Long-Term Fellow

DAVID SANTAMARIA PhD
Cancer Research UK Research Associate

DAVID SZUTS PhD
Peterhouse Research Fellow

YOSHINORI TAKEI PhD
Research Associate
ANNE McLAREN DBE DPhil FRS
Wellcome Principal Research Associate
Member, European Molecular Biology Organization
(Affiliated to Department of Zoology)

IAN ADAMS PhD
Wellcome Research Associate

GABRIELA DURCOVA-HILLS PhD
Wellcome Research Associate

MARGARET TYCE-BUTCHER
Secretary

DANIEL ST JOHNSTON PhD
Wellcome Principal Research Fellow
Member, European Molecular Biology Organization
(Affiliated to Department of Genetics)

RICHARD BENTON BA
Wellcome Prize Student

FLORIAN BOEHL PhD
EMBO Fellow

SUE CROYSDALE
Secretary

HÉLÈNE DOERFLINGER PhD
ARC Fellow

ALEJANDRA GARDIOL PhD
HFSP Fellow

JEAN-RENÉ HUYNH BA
EC Graduate Student

UWE IRION PhD
Wellcome Research Associate

VINCENT LECLERC PhD
EC Postdoctoral Fellow

KATIA LITIÈRE PhD
Wellcome Research Associate

HERNÁN LÓPEZ-SCHIER BSc
Graduate Student

NICK LOWE PhD
Wellcome Research Associate

SOPHIE MARTIN Dipl Biol
SNF Graduate Student

TRENT MUNRO PhD
HFSP Research Associate

ISABEL PALACIOS PhD
Royal Society Dorothy Hodgkin Fellow

ANTONIA PATERNÒ BA
Wellcome Senior Research Technician

ISABEL TORRES
Visiting Undergraduate Student

LUCIE WHITEHEAD BA
Wellcome Research Assistant

VITALY ZIMYANIN BSc
Darwin Trust Graduate Student
AZIM SURANI PhD FRS F Med Sci
Mary Marshall & Arthur Walton Professor of Physiology and Reproduction
Member, European Molecular Biology Organization
Member, Academia Europaea
Associate Fellow, The Third World Academy of Sciences (Affiliated to Department of Physiology)

JUSTIN AINSCOUGH PhD
Wellcome Research Associate

KATIA ANCELIN PhD
EU Marie Curie Fellow

TAKAHIRO ARIMA PhD
Japanese Government Isaac Newton Research Fellow

KATHARINE ARNEY BA
Elmore Research Student

SIQIN BAO PhD
Wellcome Research Associate

SHEILA BARTON
Wellcome Senior Research Associate

ROBERT DREWELL PhD
Wellcome Prize Research Fellow

SYLVIA ERHARDT Dipl Biol
Boehringer Ingelheim Graduate Student

ROSALIND JOHN PhD
Wellcome Research Associate

SANJEEV KHOSLA PhD
BBSRC Research Associate

CAROLINE LEE
Wellcome Chief Research Technician

MEMBERS OF THE INSTITUTE

JOANNA MALDONADO BSc
Elmore Research Student

MARY MALKIN
Secretary

NAOKI MIYOSHI PhD
Wellcome Research Associate

BERNHARD PAYER BSc
Wellcome Graduate Student

MITINORI SAITOU PhD
Wellcome Travelling Research Fellow

IRENE SZETO PhD
Croucher Foundation Fellow

PATRICK WESTERN PhD
BBSRC Research Associate

GROUP LEADERS

JULIE AHRINGER PhD
Wellcome Senior Research Fellow (Affiliated to Department of Genetics)

YAN DONG MSc
Wellcome Research Assistant

BEHROOZ ESMAEILI
BBSRC Graduate Student

ANDREW FRASER PhD
USAMC Research Associate

MONICA GOTT phys
Wellcome Research Associate

RAVI KAMATH AB
Howard Hughes Graduate Student
NATHALIE LEBOT PhD  
EU Marie Curie Fellow
GINO POULIN PhD  
CIHR Research Fellow
MIAO-CHIH TSAI  
Graduate Student
CHRISTINE TURNER  
Secretary
DAVID WELCHMAN MSc  
Wellcome Graduate Student
PEDER ZIPPERLEN Dipl Zool  
Wellcome Graduate Student

ENRIQUE AMAYA PhD  
Wellcome Senior Research Fellow  
(Affiliated to Department of Zoology)
ELENA FINEBERG CIAT  
Wellcome Senior Research Technician
ROSALIND FRIDAY BSc  
Wellcome Research Assistant
KIM GOLDSTONE  
Wellcome Chief Research Technician
MIRANDA GOMPERTS PhD  
Wellcome Career Development Fellow
KATHY HARTLEY PhD  
Wellcome Research Associate
SHOKO ISHIBASHI PhD  
EU TMR Fellow

STEPHEN NUTT PhD  
HFSP Fellow
MATTHEW POLLI PhD  
NIH Research Associate
MARGARET TYCE-BUTCHER  
Secretary

ANDREA BRAND PhD  
Wellcome Senior Research Fellow  
Member, European Molecular Biology Organization  
(Affiliated to Department of Genetics)
CLAUDIA BARROS BSc  
Portuguese FCT Graduate Student
TORSTEN BOSSING PhD  
Wellcome Research Associate
MELANIE CRANSTON BA  
Wellcome Research Assistant
CATHERINE DAVIDSON BSc  
Wellcome Research Associate
CATHERINE FRENCH BSc  
BBSRC Graduate Student
MICHAEL HEWETT BSc  
BBSRC Graduate Student
JULIA KALTSCHMIDT BSc  
Wellcome Prize Student
VAISHNAVI KRISHNAN MSc  
Nehru Scholarship Graduate Student
LESLIE MANACE BSc  
MPhil Graduate Student
MEMBERS OF THE INSTITUTE

MICHAEL MURRAY PhD
    Wellcome Research Associate
PETER VAN ROESSEL MPhil
    NSF Graduate Fellow
CHRISTINE TURNER
    Secretary

CHRISTINE STEWART PhD
    Personal Assistant
CATHY TORGLER PhD
    Swiss Government Fellow
VIKKI WILLIAMS BSc
    Wellcome Research Assistant
CHRISTOS ZERVAS PhD
    Wellcome Research Associate

RICK LIVESEY MB BChir PhD
    Wellcome Career Development Fellow
    (Affiliated to Department of Biochemistry)
JAMES SMITH BSc
    Wellcome Research Assistant

NICK BROWN PhD
    Wellcome Senior Research Fellow
    (Affiliated to Department of Anatomy)
INÉS ALVAREZ-GARCIA BSc
    Wellcome Research Assistant
CHRISTIAN BÖKEL PhD
    Wellcome Research Associate
DANELLE DEVENPORT MSc
    Wellcome Prize Student
STEPHEN GREGORY PhD
    Wellcome Research Associate
MARCUS HICKS PhD
    Wellcome Research Associate
ANDREA KNOX PhD
    Wellcome Research Associate
MAITHREYI NARASIMHA PhD
    Wellcome Research Associate
JOHN OVERTON HNC
    Wellcome Senior Research Technician
KATJA RÖPER PhD
    EMBO Fellow

NANCY PAPALOPULU PhD
    Wellcome Senior Research Fellow
    (Affiliated to Department of Anatomy)
SAMANTHA CARRUTHERS BSc
    BBSRC Graduate Student
ANDREW CHALMERS PhD
    MRC Research Fellow
PENNY DAY BSc
    BBSRC Graduate Student
ELENA FINEBERG CIAT
    Wellcome Senior Research Technician
MEMBERS OF THE INSTITUTE

ZOË HARDCASTLE
Wellcome Research Associate

SUE KENWRICK PhD
Reader, Sabbatical Visitor

BERNHARD STRAUSS MSc
Wellcome Graduate Student

MARGARET TYCE-BUTCHER
Secretary

JANA VOIGT BSc
Wellcome Graduate Student

JONATHON PINES PhD
Cancer Research UK Senior Research Fellow
Member, European Molecular Biology Organization
(Affiliated to Department of Zoology)

CLAIRE ACQUAVIVA PhD
ARC Fellow

TIM BRADBEER BA
Cancer Research UK Graduate Student

CAROLINE BROAD HNC
Cancer Research UK Senior Research Technician

NICOLE DEN ELZEN BSc
Commonwealth Scholar

VIJI MYTHILY DRAVIAM MSc
Nehru Scholar and Cancer Research UK Graduate Student

ANJA HAGTING PhD
EC TMR Fellow

MARK JACKMAN PhD
Cancer Research UK Research Associate

CATHERINE LINDON PhD
Wellcome Research Fellow

TAKAHIRO MATSUSAKA PhD
JSPS Fellow

JO RICHARDSON BA
MRC Graduate Student

JEAN-YVES THURET PhD
Sabbatical Visitor

ROB WOLTHUIS PhD
Dutch Cancer Society Research Fellow

JORDAN RAFF PhD
Wellcome Senior Research Fellow
(Affiliated to Department of Genetics)

RENATO BASTO PhD
EMBO Fellow

SUE CROYSDALE
Secretary

ANNEGRET FINLAY BSc
Wellcome Senior Research Technician

FANNI GERGELY PhD
Royal Society Dorothy Hodgkin Fellow

JUNYONG HUANG PhD
Wellcome Research Associate

KIM JEFFERS BSc
Wellcome Senior Research Technician
MEMBERS OF THE INSTITUTE

MICHAEL LEE BSc ARCS
MRC Bioinformatics Graduate Student

MARUXA MARTINEZ BSc
Wellcome Prize Student

CHODAGAM SASIDHAR BSc
Nehru Scholar

MAGDALENA ZERNICKA-GOETZ PhD
Wellcome Senior Research Fellow
(Affiliated to Department of Genetics)

STEPHEN FRANKENBERG PhD
Human Frontier Programme Research Associate

DANIEL MESNARD MSc
BBSRC Graduate Student

CATHERINE MOORE BSc
MRC Graduate Student

KAROLINA PIOTROWSKA PhD
Wellcome Research Associate

BERENIKA PLUSA
BBSRC Research Associate

BEDRA SHARIF BSc
Gates Scholarship Award Student

FLORENCE WIANNY PhD
Cancer Research UK Research Associate

SUPPORT STAFF

ADMINISTRATION
ANN CARTWRIGHT MA MPhil PGCE
Laboratory Administrator

JULIET BARROWS BA
Receptionist

DIANE FOSTER
Principal Technician

KATHY HILTON HNC
Chief Technician

LYNDA LOCKEY
Administration Assistant

LINDA MILLETT
Personnel/Administration Assistant

PAULA PEACHEY
Administration Assistant

KATE ROSSITER
Clerical Support

ACCOUNTS
JANE COOPER MAAT
Management Accountant

VERONICA SYMONDS
Accounts/Purchasing Assistant

SIMON ALDIS
Accounts/Purchasing Assistant
MEMBERS OF THE INSTITUTE

COMPUTING
DESMOND SCHMIDT PhD
Computer Associate
ALASTAIR DOWNIE
Computer Associate
NIGEL SMITH
Computer Associate
ALEX SOSSICK HNC
Computer Imaging Associate

STORES
LEN SYMONDS
Senior Storeman
RAY BOREHAM
Assistant Storeman

CUSTODIANS
DON HAYNES
Custodian
JOHN FREEMAN
Assistant Custodian

TECHNICAL SUPPORT
CAROLYN BULLMAN
Technical Assistant
CHRIS HAYLOCK
Building Services Technician
STEPHEN SALT
Equipment Support Technician

LABORATORY ASSISTANTS
JANIS ABBOTT
ROSEMARY COULSON
MARGARET HILL
YVONNE LEWIS
JOAN MENDHAM
MARGARET THODAY

MEDIA
JUANITA PEACOCK
Senior Media Technician
LINDA ADAMS
Media Technician
GAY CHALKLIN
Media Technician

CATERING
CHRISTINE CORNWELL
JOWITA NOWAK

SUPPORT STAFF

ROBIN PLUMRIDGE
DAVID SIMPSON
JOHN SWEENEY
PAULINE WHITING
KARL ZUPPINGER

MEDIA
JUANITA PEACOCK
Senior Media Technician
LINDA ADAMS
Media Technician
GAY CHALKLIN
Media Technician

LABORATORY ASSISTANTS
JANIS ABBOTT
ROSEMARY COULSON
MARGARET HILL
YVONNE LEWIS
JOAN MENDHAM
MARGARET THODAY

CATERING
CHRISTINE CORNWELL
JOWITA NOWAK
The following is a list of works by the Institute that were either published or accepted for publication in 2001.


STAFF AFFILIATIONS

JULIE AHRINGER is a Board Member of the British Society for Developmental Biology.

ANDREA BRAND is on the Scientific Advisory Board of the Promega Corporation, and is a Research Fellow at King’s College.

JOHN GURDON is Master of Magdalene College, Cambridge; Member, Conseil Scientifique of the Institut Curie, Paris, France; Member, the Scientific Advisory Board of the Max-Planck-Institut für Biophysikalische Chemie, Göttingen; and Chairman of the Company of Biologists.

STEVE JACKSON is a member of the Biochemical Society Nucleic Acids and Molecular Biology Group Committee and Chief Scientific Officer, KuDOS Pharmaceuticals Ltd.

TONY KOUZARIDES is a member of the Cancer Research UK Grants Committee, a member of the Marie Curie Institute Scientific Committee, and non-executive director of AbCam Ltd and Chroma Therapeutics.

ANNE McLAREN is a member of the Human Fertilisation and Embryology Authority, the European Group on Ethics (an advisory group to the European Commission) and is also a Trustee of the Natural History Museum.

NANCY PAPALOPULU is a Board Member of the British Society for Developmental Biology.

JON PINES is a committee member of the British Society for Cell Biology.

JORDAN RAFF is a member of the Academy of Medical Sciences’ working group on the Careers of Basic Scientists, and was made a life-long member of the Royal Institution.

DANIEL ST JOHNSTON is a Director of the Wellcome Trust Four-Year PhD programme in Developmental Biology at the University of Cambridge, and is a non-executive Director of the Company of Biologists.

JIM SMITH was co-Chair of the Academy of Medical Sciences working group on the Careers of Non-clinical Scientists and Chair of the Royal Society’s working group on Genetically Modified Plants for Food Use. He was a member of the Royal Society Working Group on the Use of Genetically Modified Animals. He is a non-executive Director of the Company of Biologists and a member of the Wellcome Trust Basic Science Interest Group.

TONY KOUZARIDES, awarded the Tenovus Medal 2001 and the Wellcome Trust Medal for Biochemical Research Related to Medicine, a Royal Society Napier Research Professorship, and made a Fellow of the Royal Academy of Medical Sciences.

ANNE McLAREN received the L’Oreal/UNESCO Women in Science 2001 Award for Europe and the US Society for Developmental Biology Award for Lifetime Scientific Achievement.

JONATHON PINES, elected Member of the European Molecular Biology Organization.


AZIM SURANI Elected Fellow of the Academy of Medical Sciences, recipient of The Royal Society Gabor Medal.

EDITORIAL BOARDS OF JOURNALS

ENRIQUE AMAYA – genesis: The Journal of Genetics and Development

ANDREA BRAND – BioEssays

JOHN GURDON – Current Biology, Development, Growth and Differentiation, International Journal of Developmental Biology

STEVE JACKSON – British Journal of Cancer, Carcinogenesis, EMBO Journal, EMBO Reports, European Life Sciences Organization Gazette, Nature Reviews, DNA Repair, Faculty of 1000 and Science

ANNE McLAREN – Gene Therapy, Current Opinion in Genetics and Development

JON PINES – Development, EMBO Journal, EMBO Reports

JIM SMITH – Development, Trends in Genetics, Current Biology, EMBO Journal, EMBO Reports

AZIM SURANI – Transgenic Research, Molecular Human Reproduction

INTERNATIONAL ADVISORY BOARD

PROF KIM NASMYTH, Research Institute of Molecular Pathology, Vienna, Austria (Chairman).

DR STEVE COHEN, European Molecular Biology Laboratory, Heidelberg, Germany.

DR TIM HUNT, Cancer Research UK, Potters Bar, UK.

PROF NIC JONES, Paterson Institute for Cancer Research, Manchester, UK.

DR JUDITH KIMBLE, Laboratory of Molecular Biology, University of Wisconsin, Madison, USA.

DR ROBB KRUMLAUF, Stowers Institute for Medical Research, Kansas City, USA.

PROF KAI SIMONS, Max-Planck-Institut of Molecular Cell Biology and Genetics, Dresden, Germany.

CHAIRMAN OF THE MANAGEMENT COMMITTEE

PROFESSOR SIR TOM BLUNDELL, Head, Department of Biochemistry, University of Cambridge.
OTHER INFORMATION

LEAVERS DURING 2001

JUSTIN AINSCOUGH is now working at the Institute for Cardiovascular Research in Leeds as a British Heart Foundation Fellow.

INES ALVAREZ-GARCIA has taken up a post-doctoral position at Harvard University, USA.

REBECCA APPELHOFF is continuing her studies at the University of Oxford.

TAKAHIRO ARIMA has returned to Japan to work as a clinician and Research Fellow at the Department of Reproduction Physiology and Endocrinology, Kyushu University.

TIM BRADBEER died suddenly on 8 August 2001.

CAROLYN BULLMAN has retired.

WENDY BURGERS is working as a post-doctoral fellow in Cape Town, South Africa.

KAREN BUTLER has left to run a public house in Royston with her husband.

ROSEMARY COULSON is now working as an insurance claim assessor.

DAMIEN D’AMOURS has taken up a postdoctoral position in Dr Angelika Amon’s Laboratory at the Center for Cancer Research, Howard Hughes Medical Institute, MIT, USA.

NICOLE DEN ELZEN has returned to Australia to a post-doctoral position at the Peter MacCallum Institute, Melbourne.

BEHROOZ ESMAEILI got his PhD in May and has taken up a post-doctoral position at the University of California, USA.

ROBERT DREWELL has taken up a post doctoral position at the Department of Molecular and Cell Biology, Berkley, University of California, USA.

DANIEL DUROCHER is working at the Samuel Lunenfeld Research Institute in Toronto, Canada.

CHRISTINE FOX has transferred to the MRC Cancer Cell Unit, Cambridge.

FRANCOIS FUKS is working at the Faculty of Medicine, Laboratory of Molecular Virology, Brussels, Belgium.

STEPHEN GREGORY has returned to Australia to take up a post doctoral position at the University of Adelaide.

ZOË HARDCASTLE is working as a Clinical Trial Assistant at Quintiles in London.

KIM JEFFERS has returned to Australia with her husband.

ROSALIND JOHN has moved to London to look after her young baby.

JULIA KALTSCMIDT is a post-doctoral fellow at the Howard Hughes Medical Institute, Columbia University, New York, USA.

ANDREA KNOX has taken up a position at the Royal Society in New Zealand.

TORSTEN KRÜDE has moved to the Department of Zoology, Cambridge.

NICHOLAS LAKIN has taken up a post doctoral post at the Department of Biochemistry, University of Oxford.

PROFESSOR RON LASKEY and the following members of his group have moved to the MRC Cancer Cell Unit, Hutchison/MRC Research Centre, Cambridge: MAGDALENA ASSENBerg, STEVE BELL, DAWN COVERLEY, GUILLERMO de la CUEVA MENDEZ, LORENA FARRACE, JACKIE MARR, TONY MILLS, CHRISTINA PELIZON, DAVID SANTAMARIA, DAVID SZUTS and YOSHINORI TAKEI.

VINCENT LECLERC is now working as a Maitre de Conference at the IBMC, Strasbourg, France.

YVONNE LEWIS is now working at Clinical Pharmacology, Cambridge.

KATIA LITIÈRE is now working for PA Consulting in Melbourn.

HERNÁN LÓPEZ-SCHIER is working at the Howard Hughes Medical Institute in New York, USA.

LESLIE MANACE is a medical student at Mount Sinai School of Medicine, New York, USA.

ANDREW MCAINSH is now working at the Department of Biology, MIT, USA.

STEPHEN NUTT is a Group Leader at the Walter & Eliza Hall Institute of Medical Research, Royal Melbourne Hospital, Australia.

PAULA PEACHEY is now working at the Department of Education, University of Cambridge.

DESMOND SCHMIDT has returned to Australia with his family.

KAZUYA SHIMIZU has returned to a post-doctoral position at Osaka University, Japan.

DONNA SMITH is continuing her PhD studies in law.

HENRIETTA STANDLEY has taken up a post-doctoral position with Dr Janet Heasman in Cincinnati, USA.

CHRISTINE STEWART left to take up a post as an Administrative Officer at the University of Cambridge Clinical School.

VERONICA SYMONDS has moved to the Department of Archaeology and Anthropology, University of Cambridge.

JEAN-YVES THURET has gone to CEA-SACLAY, France.

ELIZABETH TWEED has retired.

BRANDI WILLIAMS is now working for Myriad Genetics in Utah, USA.

LUCIE WHITEHEAD has moved to the Department of Anatomy, University of Cambridge.

JOOST WOOLTERING returned to Holland to finish his degree.
ACKNOWLEDGEMENTS
Prospectus produced in the Wellcome Trust/Cancer Research UK Institute, edited by Jane Bradbury and Ann Cartwright. Photography by Chris Green (Biochemistry) and Alex Sossick. Printed by Cambridge University Press.

Front cover image by Maithreyi Narasimha, Brown Group: A section through the Drosophila embryo stained for integrin (green) and actin (red).

Back cover: The Institute’s new building progresses.
Our new building under construction

The Wellcome Trust and Cancer Research UK
Institute of Cancer and Developmental Biology
University of Cambridge
Tennis Court Road, Cambridge CB2 1QR
Telephone: +44 (0)1223 334088
Fax: +44 (0)1223 334089
http://www.welc.cam.ac.uk
e-mail: info@welc.cam.ac.uk